Deals this week: AmpliPhi Biosciences, Argos Therapeutics, Juvenescence Limited

12th January 2018 (Last Updated August 12th, 2019 10:39)

AmpliPhi Biosciences Corp plans to issue shares of its common stock in a public offering.

AmpliPhi Biosciences Corp plans to issue shares of its common stock in a public offering.

The US-based clinical-stage biotechnology company plans to use proceeds for general corporate expenses.

US-based immuno-oncology company Argos Therapeutics Inc plans to raise $1.5m through the private placement of 7.5 million shares of its common stock priced at $0.20 a share.

Lummy Hong Kong Co Ltd has subscribed to the private placement.

Juvenescence Limited has raised $12.3m in seed financing from angel investors and institutions that include Foresite Capital, Karim Hakimzadeh, Andrew Banks and Christian Angermayer’s Apeiron Investment Group.

In addition, founders of the company chairman Jim Mellon and chief executive officer Gregory Bailey each provided $1.5m.

Juvenescence is a UK-based company involved in the development of therapeutics for ageing and age-causing diseases. The company plans to use the funds to form collaborations with academic institutions.

"The latest transaction has increased the total amount raised to $21.63m."

Alder Biopharmaceuticals Inc plans to raise $250m through the private placement of shares of its class A preferred stock.

The placement will be subscribed to by affiliated institutional and accredited investors.

The biopharmaceutical company plans to use the funds towards the payment of European patent settlement and signing a global licence agreement with Teva Pharmaceuticals International GmbH, as well as for working capital and general corporate purposes.

Storm Therapeutics Ltd (formerly Iceni Therapeutics) has secured £4m ($5.42m) in a series A financing round led by Taiho Ventures LLC, the venture capital division of Taiho Pharmaceutical Co Ltd.

Storm previously raised £12m ($15.96m) in June 2016 from existing investors, Imperial Innovations Group Plc, Cambridge Innovation Capital Plc, Merck Ventures BV and Pfizer Venture Investments.

The latest transaction has increased the total amount raised to £16m ($21.63m).

The US-based cancer drug development company plans to use funds to expand its pipeline and broaden its drug discovery platform.